885066-11-5

Basic information

• Product Name: 4-Pyrimidinamine, 6-chloro-2-methoxy-N-[2-[4-(trifluoromethoxy)phenyl]ethyl]-
• CAS NO: 885066-11-5
• Molecular Formula: C14H13ClF3N3O2
• Molecular Weight: 347.724
• Mol File: 885066-11-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-Pyrimidinamine, 6-chloro-2-methoxy-N-[2-[4-(trifluoromethoxy)phenyl]ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyrimidinamine, 6-chloro-2-methoxy-N-[2-[4-(trifluoromethoxy)phenyl]ethyl]-(885066-11-5)
• EPA Substance Registry System: 4-Pyrimidinamine, 6-chloro-2-methoxy-N-[2-[4-(trifluoromethoxy)phenyl]ethyl]-(885066-11-5)

Safety Data

• Hazardous Substances Data: 885066-11-5(Hazardous Substances Data)

Upstream product

• 1074-40-4 4,6-dichloro-2-methoxypyrimidine 
• 49561-96-8 (4-trifluoromethoxy-phenyl)-acetonitrile 

Downstream Products

• 1334406-57-3 (2-methoxy-6-morpholin-4-ylpyrimidin-4-yl)-[2-(4-trifluoromethoxyphenyl)ethyl]amine 
• 1334406-46-0 4-(1-{2-methoxy-6-[2-(4-trifluoromethoxyphenyl)ethylamino]pyrimidin-4-yl}piperazine)-1-carboxylic acid ethyl ester 
• 1334406-47-1 1-{2-methoxy-6-[2-(4-trifluoromethoxyphenyl)ethylamino]pyrimidin-4-yl}-3-methylpyrrolidine-3-carboxylic acid 
• 1334404-28-2 (1-{2-methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-piperidin-3-yl)-acetic acid ethyl ester 
• 1334404-24-8 (S)-(1-{2-methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-piperidin-3-yl)-acetic acid 
• 1334404-25-9 (R)-(1-{2-methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-piperidin-3-yl)-acetic acid 
• 1334404-23-7 (1-{2-methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-piperidin-3-yl)-acetic acid 
• 1334404-29-3 C₂₃H₂₉F₃N₄O₄ 
• 885069-69-2 5-{2-methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-2,3-dihydro-benzofuran-2-carboxylic acid 
• 885068-53-1 2-(2-fluoro-5-{2-methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid methyl ester 

Relevant articles and documents

SUBSTITUTED PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed to a substituted pyrimidine compound of formula (I) as set forth herein, or an enantiomer thereof, or a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. Th

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).